Cervixept

Quick links to important sections

Cervixept

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cervixept

Cervixept is a brand name medication available in several dosage forms, including vaginal ovules (suppositories), gel, and solution. It is specifically designed for topical application to the vagina and cervix. The active pharmaceutical ingredient in all formulations is Policresulen (also known as Policresulene). This drug is a topical antiseptic and hemostatic agent that works locally on tissue, and it is a popular product in several Central and South American countries.


Therapeutic Role

Cervixept is primarily indicated for the local management of various gynecological conditions affecting the cervix and vaginal mucosa. It is commonly used as a coadjuvant treatment for inflammatory states, exudative lesions, and infections caused by various pathogens, including bacteria, fungi (such as Candida albicans), and Trichomonas. A key characteristic is its debriding (keratolytic) and tissue-regenerating (keratoplastic) properties, which help promote the healing of damaged tissue.


Unique Features and Recognized Use

A notable use for Cervixept, particularly the ovule and solution forms, is as an aid in colposcopy procedures. It is clinically recognized for its hemostatic (bleeding control) and cicatrizing (scar-forming/healing) effects following minor procedures such as cervical biopsies, removal of polyps, or post-cryotherapy treatments. Because its large molecular size limits systemic absorption, its therapeutic actions are concentrated on the target tissue. The medicine also possesses astringent properties, which contribute to decreasing excessive vaginal secretions associated with some conditions.

What side effects are possible with Cervixept?

Possible Side Effects and Safety Information

This section describes the officially documented adverse reactions and safety characteristics of Cervixept (Policresulen), as classified by government regulatory authorities.


Frequency-Classified Adverse Reactions

The safety profile is primarily defined by effects localized to the application area, classified under the Reproductive system and breast disorders.

Classification Adverse Reaction
Very Common (≥ 1/10) Vaginal dryness
Common (≥ 1/100 to < 1/10) Burning sensation or pain in the vagina; Discharge of shreds of mucous membrane
Not Known Systemic allergic reactions, including anaphylaxis and angioedema

The burning sensation is sometimes noted as an occasional event that is typically expected to soon disappear, suggesting a transient nature. The discharge of tissue shreds is a documented safety pattern, reflecting the drug's intended action on damaged or necrotic tissue.


Population-Specific Safety Considerations

Official labeling includes specific cautions for certain populations:

  • Pregnancy: Treatment involving the cervix is advised against, especially during the third trimester. Use for the vagina and surrounding areas requires careful assessment of potential risks to the mother and fetus.
  • Lactation (Breastfeeding): Use requires consideration of the potential for harm to the infant.

General Safety Constraints

  • Eye Contact: The medication should be prevented from contacting the eyes.

The overall safety profile is structured by these common local effects and the documented, though rare, risk of serious systemic immune reactions.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documents define the required actions and immediate concerns for overdose or overexposure to products similar to Cervixept. Overdose information is primarily structured around high-level exposures and the institution of symptomatic care.

Overdose Context Documented Manifestation Emergency Action Required
Massive oral overdose Signs of adrenal failure Close observation for signs of adrenal failure
Excessive topical application Severe application site reactions, including skin weeping and erosion Discontinuation of use and appropriate symptomatic care
General Overdose Dizziness, drowsiness, nausea, vomiting, or breast tenderness Discontinuation of therapy and institution of appropriate symptomatic care

Immediate medical attention is necessary if any of the following symptoms occur, as these can indicate a serious issue:

  • Severe, prolonged heavy bleeding (such as soaking through two full-size pads per hour for two continuous hours).
  • Sustained fever (100.4°F or higher that lasts more than four hours).
  • Severe abdominal pain, general malaise, or discomfort that persists for more than 24 hours.
  • Fainting or syncope.

In the event of an overdose or accidental ingestion, particularly a massive overdose, the product should be discontinued immediately. Treatment should focus on supportive and symptomatic care guided by a healthcare professional. For topical overexposure, washing the area with mild soap and water may be necessary, and treatment can be resumed once the local skin reaction has moderated.

Therapeutic Uses of Cervixept

What Cervixept Treats: Main Uses and Benefits

Cervixept (Policresulen) is commonly used to provide localized symptomatic and restorative support for various gynecological and tissue-related conditions. This medication is applied across therapeutic domains involving local inflammation, infection, and tissue damage on the cervix and vagina. This therapeutic support commonly contributes to improved day-to-day comfort during symptomatic periods.

It is commonly used for managing conditions that include cervicitis, vaginitis, cervical erosion, and localized ulcers, such as those caused by pessaries. The treatment focuses on supporting the repair of damaged tissue and addressing symptoms like excessive vaginal secretions (leucorrhea), irritation, and minor, localized bleeding. The medication may assist with localized hemostasis (minor bleeding management) and supports the healing (cicatrization) of the tissue site.

In clinical settings, Cervixept is relevant when supportive symptom management is appropriate, such as following minor office-based procedures like a cervical biopsy or the removal of polyps. Its use assists with maintaining a sense of stability when symptoms are more noticeable.


Quick Fact: Relief for Localized Bleeding The medication is relevant in post-procedural contexts to help address and manage minor, localized bleeding events.

Regulatory References

  1. DailyMed listing on the NIH website

Eligibility and Restrictions for Use

The eligibility for Cervixept (Policresulen) is strictly defined by regulatory labeling, concentrating on reproductive status, age, and procedural timing.

Contraindications

Use is absolutely contraindicated in patients with a known hypersensitivity to Policresulen or any components. Furthermore, any treatment of the cervix is contraindicated during pregnancy, particularly in the third trimester, due to the risk of inducing labor.

Age-Group Exclusions

The medicine is not indicated for use in children and adolescents under the age of 18 years, as official documents state that safety and efficacy data have not been established in these populations. The same regulatory restriction applies to postmenopausal women, for whom use is similarly not indicated due to a lack of clinical experience in this group.

Conditional and Restricted Use

Use is conditional on the physiological status of the patient. Treatment must be stopped during menstruation. For pregnant patients, vaginal use is restricted and permitted only when absolutely necessary, with application to the cervix remaining forbidden. For breastfeeding patients, use is restricted as it is officially unclear whether the active ingredient is excreted in human milk. No explicit restrictions are documented for severe hepatic or renal impairment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Cervixept (Policresulen) is defined by its method of administration and localized action. Because the medication is intended solely for topical application to the cervix and vagina, with negligible systemic absorption, government regulatory documents indicate that systemic drug-drug interactions, such as those involving CYP enzymes or drug transporters, are not documented in the official prescribing information.

The primary interactions are local restrictions related to co-administration and chemical environment.

Local Co-Administration Restrictions

The co-administration of Cervixept with other medicinal products for vaginal use (including creams, gels, and suppositories) is strictly restricted or classified as avoided in regulatory labels. This prohibition is mandatory during the course of treatment because interactions between the agents in the local area cannot be excluded, as stated in official prescribing information.

Chemical Incompatibility

The active ingredient, Policresulen, is an organic acid with a highly acidic nature. This creates a documented risk of chemical incompatibility that can potentially compromise the physical structure of certain materials. Due to this factor, the use of latex-based barrier contraceptives (such as condoms or diaphragms) is restricted during treatment. No specific interactions with food, alcohol, or herbal products are documented in official regulatory sources.

Mechanism of Action

Policresulen's mechanism of action is strictly local and multifaceted, driven by its properties as a strong polymeric acid, focusing its effects entirely at the site of application. The primary function is the selective coagulation and denaturation of proteins in pathologically altered tissue. This chemical action forms a non-viable protective eschar, which sloughs off, resulting in chemical debridement that exposes and stimulates the underlying tissue for reepithelialization and repair.

The drug also exerts a dual hemostatic action. It coagulates proteins within the walls of superficial capillaries, inducing localized vasoconstriction through myofibril contraction. Simultaneously, it precipitates plasma proteins, forming a physical hemostatic plug that leads to the cessation of superficial blood flow.

Furthermore, Policresulen provides a broad antiseptic effect. Its high local acidity disrupts the structural integrity of microbial cell membranes and impairs essential metabolic functions, leading to a reduction of the local pathogen concentration at the application site.

Dosage and Administration Information

How Cervixept is Used

Cervixept (Policresulen) is administered according to established instructions that govern the route, frequency, and duration of its use. The medication is available primarily for topical application via vaginal ovules (suppositories), and as a solution or gel for both professional and self-administered use. The concentrated solution also possesses an approved use as a buccal/oral rinse for specific indications.

Official Administration and Scheduling

The standard regimen for the vaginal ovule involves the insertion of one ovule high into the vagina on an intermittent schedule of once every two days. To facilitate proper application, the ovule can be briefly immersed in water and is required to be inserted in the evening before going to sleep, preferably while lying in the supine position. Treatment must adhere to a defined time frame and is typically not to exceed 9 days. For the oral rinse solution, the official schedule is up to four times daily, generally after meals and at bedtime.

Course Constraints and Handling

Instructions mandate that treatment with vaginal forms must be stopped entirely during the menstrual period, which imposes a specific, cycle-dependent constraint on the overall duration of use. Furthermore, administration is often associated with the requirement to use a sanitary pad to manage discharge and prevent soiling, which is a practical constraint related to the expected effect of the drug on tissue. Use of the gynecological form is generally not indicated for postmenopausal women due to a lack of clinical experience in that population.

Recent Clinical Evidence

Cervixept: Recent Clinical Evidence

Evidence for Use in Managing Vaginocervical Inflammation

Research examined conditions characterized by inflammatory or irritative states, such as cervicitis, vaginitis, and symptoms related to the Genitourinary Syndrome of Menopause (GSM). The available evidence includes Randomized Controlled Trials (RCTs) and Controlled Clinical Trials. These comparative study designs are relevant in trials assessing short-term or episodic symptom patterns. Studies monitored outcomes related to physical discomfort and outcomes linked to inflammatory or irritative states, reporting how symptoms evolved in the observed populations during short to intermediate follow-up periods.


Research on Post-Procedural Tissue Support

Research examined the application of Policresulen for procedural support following minor office interventions, such as cervical biopsies or the removal of polyps. Studies explored its use in outcomes related to localized hemostasis (minor bleeding control) and tissue regeneration. This evidence is largely derived from Clinical Observation reports and supportive non-comparative studies. These studies monitored the cessation of minor bleeding and the rate of tissue repair. The findings describe group patterns, not personal outcomes.


Limitations and Research Uncertainty

Types of Clinical Trials and Patient Populations: The available evidence quality varies across studies and is heterogeneous. While RCTs contribute to a Moderate Evidence Level for the inflammation indication, the evidence level for post-procedural uses is characterized by the reliance on descriptive or non-comparative data. Comparative evidence is lacking against other topical agents used for hemostasis. Research examined adult women, including specific cohorts such as post-menopausal women, but data for certain groups remain insufficient.

Long-Term Follow-up: Most studies exploring short-term symptom changes were limited in their follow-up durations. Consequently, long-term effects are not fully established, and there is limited information for long-term outcomes to describe the evolution of tissue status or symptom patterns over extended periods.

Key Studies & References

  1. Instruction for Usage of Policresulen Vaginal Suppository (Albothyl) - DailyMed
  2. Uses of Albothyl medicine (Policresulen indications/mechanisms)

Frequently Asked Questions (FAQ)

Common questions about Cervixept (FAQ)


Q: Is it normal to feel a little stomach upset when first starting Cervixept?

Official documents classifying the adverse reactions of Cervixept primarily describe localized effects at the application site, such as a burning sensation or vaginal dryness. Gastrointestinal issues, including stomach upset, are not listed among the commonly reported side effects in the official product information.


Q: Can Cervixept be taken at the same time as vitamin supplements or herbal products?

Regulatory documents state that due to the localized action and negligible systemic absorption of Cervixept, no specific systemic interactions with herbal products or vitamin supplements are documented. However, the co-administration of Cervixept with other medicinal products for vaginal use is restricted.


Q: Do I need to take Cervixept with a full meal or on an empty stomach?

The official instructions for the vaginal ovule formulation specify that it should be inserted in the evening before going to sleep. This timing requirement relates to the administration route and is not connected to having a meal or being on an empty stomach.


Q: Can people with liver problems use Cervixept?

According to official regulatory documents, no explicit restrictions or specific recommendations for dose adjustment are documented for patients who have severe hepatic (liver) or renal (kidney) impairment.


Q: Are there any known long-term side effects associated with Cervixept use?

Official summaries of clinical research indicate that most studies monitoring the effects of the medication were limited to short-term follow-up periods. Therefore, information describing the full range of long-term safety outcomes and effects is not fully established.


Q: What happens if I miss a scheduled dose of Cervixept?

Official guidance for a missed dose describes that continuing with the next scheduled dose at the usual time, maintaining the prescribed administration frequency, is the typical protocol.


Q: Is it necessary to store Cervixept in the refrigerator?

Official storage instructions state that the product must be stored at a temperature below 25 C and protected from moisture and light. Refrigeration is not typically required unless the ambient room temperature where the medication is kept consistently exceeds this limit.


Q: What is the chance of having a severe allergic reaction to Cervixept?

Official safety classifications categorize systemic allergic reactions, such as anaphylaxis or angioedema (severe swelling), with a frequency of Not Known. This means that based on the available data, the exact chance or frequency of these severe reactions cannot be reliably estimated.


Q: How quickly should I expect Cervixept to start having an effect?

The medication's mechanism of action is described as an immediate process. The selective coagulation and denaturation of proteins in the altered tissue at the application site occurs very quickly, beginning the necessary debridement process upon contact.


Q: Does Cervixept treat the symptoms or the underlying condition?

Regulatory documents describe Cervixept as a local antiseptic and hemostatic agent. Its therapeutic role is to manage inflammatory symptoms and promote tissue healing as a coadjuvant (supportive) treatment for various gynecological conditions.


Q: Can I take over-the-counter pain relievers with Cervixept?

Official regulatory documents do not list interactions with systemic medications like oral over-the-counter pain relievers. This is because the drug has negligible systemic absorption, meaning its action is concentrated only at the site of application.


Q: Does Cervixept interact with common birth control medications?

Official regulatory labels restrict the use of latex-based barrier contraceptives (like condoms or diaphragms) due to chemical incompatibility. However, they do not document systemic interactions with hormonal birth control medications.


Q: Is Cervixept known to cause drowsiness or affect sleep patterns?

The official side effect classifications for Cervixept are focused on local reactions at the application site. Adverse reactions involving the central nervous system, such as drowsiness or changes in sleep patterns, are not listed among the reported side effects.


Q: Is Cervixept linked to any issues with weight gain or loss?

Official adverse reaction documents do not list metabolic changes, such as weight gain or weight loss, among the commonly reported side effects of Cervixept. The medication’s action is localized with negligible systemic impact.


Q: Is it true that Cervixept can cause changes in mood or anxiety?

Official regulatory documents classifying the adverse reactions of the medication do not list psychiatric or mood-related effects. Changes in mood or anxiety are not among the commonly reported side effects.


Q: Does Cervixept have any known interaction with grapefruit or grapefruit juice?

Regulatory documents report negligible systemic absorption and state that no specific interactions with food, including items such as grapefruit or grapefruit juice, are documented in official prescribing information.


Q: Is there a generic version of Cervixept available for use?

Cervixept is a specific brand name. However, the active ingredient, Policresulen, is recognized globally and is available under various brand names, suggesting that non-branded or authorized generic forms may exist depending on the specific country's regulatory market.


Q: Is Cervixept considered a controlled substance?

Cervixept (Policresulen) is a topical antiseptic and hemostatic agent. Official regulatory bodies classify controlled substances as those with potential for abuse, and Cervixept is not included in this classification.


Q: Can Cervixept be safely used in teenagers?

Official documents state that Cervixept is not indicated for use in children and adolescents under the age of 18 years. This restriction is because safety and efficacy data have not been established in this younger age group.


Q: Why do some people need to take Cervixept, but others don't?

The need for Cervixept is based on individual medical necessity and diagnosis. The medication is indicated for the local management of specific gynecological conditions affecting the cervix and vaginal mucosa, such as inflammatory states and exudative lesions.


Q: What is the evidence regarding Cervixept's use in long-term treatment?

Official research summaries state that most clinical studies were limited to short-term follow-up durations. Therefore, available evidence describing the effects and status of the tissue during long-term treatment is considered limited.

How should Cervixept be stored and disposed of?

How to Store and Dispose of Cervixept

The storage of Cervixept (Policresulen) must strictly adhere to the conditions documented in official regulatory labeling to ensure product stability.

Storage Requirements

  • Temperature: Store the product at a temperature that is below 25 C (77 F), as exceeding this limit can affect the integrity of the ovules.
  • Protection: The medication must be protected from both moisture and direct light. It is necessary to keep the product in its original package and ensure multi-dose containers are tightly closed.
  • Handling: The product should not be frozen, as this can compromise the physical form. Do not use the medicine after the expiration date printed on the container.
  • Child Safety: Cervixept must be kept out of the sight and reach of children.

Disposal Instructions

Expired or unused Cervixept must be disposed of according to local regulations. Medicines should not be disposed of via household waste or wastewater (such as flushing down a toilet or sink). Disposal must comply with authorized pharmaceutical waste programs.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cervixept found in:

A-Z Index: